glp receptor 1 agonists Glucagon-like peptide-1 (GLP-1) are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic Glucagon-like peptide 1(GLP-1) receptor agonists

This release can result in pancreatic edema, causing enzymes and other toxic substances to be trapped within the pancreas and leading to tissue damage in the pancreas and acute pancreatitis

Medication Shortages Patients lost progress when they couldnt access prescriptions

The most common reasons for stopping GLP1RAs and tirzepatide are gastrointestinal intolerance and high costs

GLP-1RAs hold promise as dual-action agents in IBD, offering potential benefits in metabolic control, weight loss, and disease modulation through immunological and barrier-enhancing effects

doi: 10.1016/j.cmet.2019.03.002 61 GrunddalKVJensenEPrskovCAndersenDBWindelvJAPoulsenSSet al

Are GLP-1 drugs being tested for benefits beyond weight loss